Lymphocytes sorted from cancer biopsy samples were expanded by interleukin 2 (IL-2) treatment and reinfused into the patient with subcutaneous IL-2 [9], resulting in an initial outcome of 34% efficacy, with a median response of 4 months [9]. This evidence concerns the gene IL2 and cancer.